Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03259035
Other study ID # CO28
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date June 29, 2018
Est. completion date April 25, 2024

Study information

Verified date April 2024
Source Canadian Cancer Trials Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to find out the effects of chemotherapy followed by less invasive surgery on patients and their early rectal cancer. The approach of this trial will be considered a success if at least 65% of participants are able to keep the rectum.


Recruitment information / eligibility

Status Completed
Enrollment 58
Est. completion date April 25, 2024
Est. primary completion date April 8, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically confirmed invasive well-moderately differentiated rectal adenocarcinoma diagnosed within 90 days prior to enrollment. - Tumour stage cT1-T3abN0 based on pelvic MRI - cT1N0- tumour invasion into submucosa, no radiographic evidence of mesorectal nodal metastasis, tumour deposits or vascular invasion. - cT2N0 - tumour invasion into muscularis propria, no radiographic evidence of mesorectal nodal metastasis, tumour deposits or vascular invasion. - cT3a,bN0- tumour invasion through the muscularis propria no more than 5 mm into the subserosa/perirectal tissue and clear of the circumferential radial margin (CRM). Absence of radiographic evidence of mesorectal nodal metastasis, tumour deposits or lymphovascular invasion. Note: If the tumour is not visualized in the MRI but there is histological confirmation of rectal adenocarcinoma the patient is eligible. - cN0 stage based on pelvic MRI. Any nodes = 10 mm in longest dimension are considered malignant, regardless of nodal morphology. For pelvic nodes < 10 mm in longest dimension, if nodes are seen and are deemed to be morphologically benign in the opinion of the radiologist and surgeon, the patient is eligible. Patients with visible pelvic sidewall nodes are excluded - M0 stage based on no evidence of metastatic disease by CT imaging. - Mid to low-lying tumour eligible for local tumour excision in the opinion of the treating surgeon. - Age of at least 18 years. - Medically fit to undergo radical surgery as per treating surgeon's discretion - No contraindications to protocol chemotherapy. - Adequate normal organ and marrow function as defined below (must be done within 30 days prior to enrolment): - ANC = 1.5 x 109/L - platelet count =100 x 109/L - bilirubin < 1.5 ULN, excluding Gilbert's syndrome - Calculated creatinine clearance of = 50 ml/min. - Clearance to be calculated using Cockcroft formula: Males: 1.23 x (140 - age) x weight (kg) - serum creatinine (µmol/l) ; Females: 1.05 x (140 - age) x weight (kg) - serum creatinine (µmol/l) - The patient must have an ECOG performance status of 0, 1. - Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life and health utility questionnaires. - Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate. - Must be accessible for treatment and follow up. Patients registered on this trial must be treated with chemotherapy and followed at the enrolling centre. - Protocol treatment is to begin within 5 working days of patient enrollment. - Women/men of childbearing potential must have agreed to use a highly effective contraceptive method during and for 6 months after completion of chemotherapy. Exclusion Criteria: - Patient has pathologic high risk factors on either the initial biopsy specimen report or follow-up biopsy (if done): high histologic grade, mucinous histology, lymphatic or vascular invasion. - History of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for = 5 years. - Synchronous cancer. - Prior treatment for rectal cancer. - Previous pelvic radiation for any reason. - Patients with known dihydropyrimidine dehydrogenase deficiency - Treatment with other investigational drugs or anti-cancer therapy within 28 days prior to enrolment. - Clinically significant (i.e. active) cardiovascular disease for example cerebro vascular accidents (< 6 months prior to enrolment), myocardial infarction (< 6 months prior to enrolment), unstable angina, New York Heart Association (NYHA) grade II or higher, congestive heart failure, serious cardiac arrhythmia requiring medication. - Any contra-indications to undergo MRI imaging.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Folfox Protocol
6 cycles of q2weekly FOLFOX, or
Capox
4 cycles of q3weekly CAPOX

Locations

Country Name City State
Canada QEII Health Sciences Centre Halifax Nova Scotia
Canada Kingston Health Sciences Centre Kingston Ontario
Canada The Research Institute of the McGill University Montreal Quebec
Canada Ottawa Hospital Research Institute Ottawa Ontario
Canada Health Sciences North Sudbury Ontario
Canada BCCA - Vancouver Cancer Centre Vancouver British Columbia
Canada St. Paul's Hospital Vancouver British Columbia
Canada CancerCare Manitoba Winnipeg Manitoba
United States Dana-Farber Cancer Institute Boston Massachusetts
United States UC Irvine Medical Center Orange California
United States Virginia Mason Medical Center Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
Canadian Cancer Trials Group

Countries where clinical trial is conducted

United States,  Canada, 

References & Publications (1)

Kennecke HF, O'Callaghan CJ, Loree JM, Moloo H, Auer R, Jonker DJ, Raval M, Musselman R, Ma G, Caycedo-Marulanda A, Simianu VV, Patel S, Pitre LD, Helewa R, Gordon VL, Neumann K, Nimeiri H, Sherry M, Tu D, Brown CJ. Neoadjuvant Chemotherapy, Excision, and — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Measurement of organ preservation rate The primary endpoint of this study is the protocol specified organ preservation rate, defined as the proportion of patients with tumour downstaging to ypT0/T1good N0 and who avoid radical surgery. The 95% confidence interval for the organ preservation rate will be calculated 3 years
Secondary Locoregional Relapse Rate (LRR) 3 years
Secondary Distant Relapse Rate (DRR) estimated based on Kaplan-Meier method 3 years
Secondary Disease Free Survival (DFS) estimated based on Kaplan-Meier method 3 years
Secondary Rate of post-operative complications 3 years
Secondary Number and severity of adverse events using CTCAE V5 3 years
Secondary Quality of Life using QLQ-C30 3 years
Secondary Cost effectiveness using the EQ-5D-5L questionnaire 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT06380101 - Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC) N/A
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Recruiting NCT04323722 - Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04088955 - A Digimed Oncology PharmacoTherapy Registry
Active, not recruiting NCT01347697 - Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer N/A
Recruiting NCT04495088 - Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer Phase 3
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Terminated NCT01347645 - Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer Phase 1/Phase 2
Not yet recruiting NCT03520088 - PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS N/A
Recruiting NCT05556473 - F-Tryptophan PET/CT in Human Cancers Phase 1
Recruiting NCT04749381 - The Role of TCM on ERAS of Rectal Cancer Patients Phase 2
Enrolling by invitation NCT05028192 - Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
Recruiting NCT03283540 - Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Recruiting NCT05914766 - An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer N/A
Recruiting NCT04852653 - A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
Recruiting NCT03190941 - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Phase 1/Phase 2
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A
Terminated NCT02933944 - Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer Phase 1